What is IDAP? As the IDAP pilot opens, we explore how this new pathway offers a fast-track route to patient access for innovative medical technologies.
Read More
Calum Jones (Associate Director – Health Economics) shares his experience speaking at the 2024 HTAi Conference. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’.
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US and highlight important considerations for companies seeking to infiltrate this key market.
We bring together specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024-25. Jump in, as our experts give their hot-take on each trend, sharing their perspectives on what’s happening in these areas.
Discover 11 common problems that may arise when cost-cutting compromises the quality of your systematic literature review.
What actions can you take in light of ISPOR’s top 10 HEOR trends? What impact may these issues have on your HEOR and Market Access strategy?
In this webinar, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies. Have you established the clinical and economic value of your medical device, diagnostic or...
Read More
We are delighted to announce that the second edition of our popular introductory guide: ‘Market access and reimbursement in key European markets’ is now available. Our market access experts have...
Read More
We are delighted to announce that Mtech Access are now a certified NICE Medtech Early Technical Assessment (META) Tool facilitating organisation. Samantha Gillard (Director – HTA), Persefoni Ioannou (Consultant –...
Read More
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
